- The FDA clears Luminex's (NASDAQ:LMNX +0.5%) ARIES Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women, the third test cleared for use on the ARIES Systems. It has received CE-IVD marketing as well.
- The ARIES GBS Assay is a real-time polymerase chain reaction (PCR)-based diagnostic test designed to detect Group B Streptococcus nucleic acid from 18 - 24-hour Lim broth-enriched vaginal-rectal swab specimens obtained from pregnant women.